A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation

Infection

Volumn 40, Issue 6, 2012, Pages 669-675

  Greiner, M ^a   Cusini, A ^a   Ruesch, M ^a   Schiesser, M ^a   Ledergerber, B ^a   Fehr, T ^a   Mueller, N J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adherence; CMV disease; Cytomegalovirus; Preemptive therapy; Prophylaxis

Indexed keywords

ANTIMETABOLITE; BASILIXIMAB; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; NON CALCINEURIN INHIBITOR; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; OUTPATIENT; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT RESPONSE; VIREMIA;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND; TIME FACTORS; VIRAL LOAD; VIREMIA;

EID: 84874105701     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0343-5     Document Type: Article

References (10)

1. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in highrisk kidney transplant recipients. Am J Transplant. 2010;10(5): 1228-37.
2. Helantera I, Kyllonen L, Lautenschlager I, Salmela K, Koskinen P. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant. 2010;10(9):2026-32.
3. Humar A, Michaels M. American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2): 262-74.
4. Yun Z, Lewensohn-Fuchs I, Ljungman P, Vahlne A. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays. Transplantation. 2000;69(8):1733-6.
5. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-60.
6. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779-95.
7. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8(5):975-83.
8. Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation. 2010;90(4):412-8.
9. Zhang LF, Wang YT, Tian JH, Yang KH, Wang JQ. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials.Transpl Infect Dis. 2011;13(6):622-32.
10. Luan FL, Kommareddi M, Ojo AO. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation. 2011;91(2):237-44.